Odanacatib

Drug Profile

Odanacatib

Alternative Names: MK-0822; MK-822

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Celera Group
  • Developer Banyu; Merck & Co
  • Class Amides; Biphenyl compounds; Cyclopropanes; Nitriles; Osteoporosis therapies; Small molecules; Sulfones
  • Mechanism of Action Bone resorption factor inhibitors; Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone metastases; Corticosteroid-induced osteoporosis; Male osteoporosis; Osteoarthritis; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 26 Sep 2016 Merck Sharp & Dohme terminates a phase I trial in Corticosteroid-induced osteoporosis (In adolescents, Prevention, In adults) in USA, United Kingdom, Italy and Finland (NCT01630616, EudraCT2012-003414-14)
  • 16 Sep 2016 Efficacy and adverse events data from an extension study of the phase III LOFT trial in Osteoporosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research
  • 02 Sep 2016 Discontinued - Phase-I for Corticosteroid-induced osteoporosis (In adolescents, Prevention, In adults) in United Kingdom, Italy, Finland, South Korea, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top